Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.

Bullish (Video) Percheron Horses: Daily Life on a Hidden Valley Farms Horse Breeding Operation Posted: February 21, 2025 | Last updated: March 8, 2025 The film showcases the daily operations of ...

The ASX200 is set to open 0.15% lower today, reflecting mixed performances among US markets, with notable movements in the Dow and tech sector fluctuations impacting investor sentiment. In such a ...